Cargando…
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
OBJECTIVES: The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. TRIAL DESIGN: This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and...
Autores principales: | Eckhardt, Christina M., Cummings, Matthew J., Rajagopalan, Kartik N., Borden, Sarah, Bitan, Zachary C., Wolf, Allison, Kantor, Alex, Briese, Thomas, Meyer, Benjamin J., Jacobson, Samuel D., Scotto, Dawn, Mishra, Nischay, Philip, Neena M., Stotler, Brie A., Schwartz, Joseph, Shaz, Beth, Spitalnik, Steven L., Eisenberg, Andrew, Hod, Eldad A., Justman, Jessica, Cheung, Ken, Lipkin, W. Ian, O’Donnell, Max R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276974/ https://www.ncbi.nlm.nih.gov/pubmed/32513308 http://dx.doi.org/10.1186/s13063-020-04422-y |
Ejemplares similares
-
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
por: Eckhardt, Christina M., et al.
Publicado: (2020) -
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
por: Eckhardt, Christina M., et al.
Publicado: (2020) -
METABOLOMIC PROFILING AND PROGNOSTICATION IN COVID-19-RELATED ARDS
por: FURFARO, DAVID, et al.
Publicado: (2022) -
Screening for Viral Infections
por: Lipkin, Walter Ian, et al.
Publicado: (2021) -
Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)